22 companies, publicly listed.
BrainsWay
Neurotechnology & BCI · Deep transcranial magnetic stimulation
Latest (Oct 26, 2026): BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives
Open profile →Longeveron
Longevity · Regeneration · Cell therapy for ageing-related and other conditions
Latest (Oct 26, 2026): Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Open profile →Lifeward
Physical augmentation · Exoskeletons and rehabilitation technology
Latest (Oct 27, 2026): Lifeward reports changes involving its directors or officers (Form 8-K, Item 5.02)
Open profile →Myomo
Physical augmentation · Powered arm and hand orthoses
Latest (Oct 5, 2026): Department of Veterans Affairs obligates $31,635 to Myomo
Open profile →Nexalin Technology
Neurotechnology & BCI · Non-invasive brain stimulation devices
Latest (Sep 28, 2026): Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in Its Transition Toward Commercial Revenue Generation
Open profile →electroCore
Neurotechnology & BCI · Non-invasive vagus nerve stimulation
Latest (Sep 8, 2026): electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers
Open profile →Humacyte
Regeneration · Bioengineered human tissue
Latest (Sep 22, 2026): Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Open profile →Neuronetics
Neurotechnology & BCI · Transcranial magnetic stimulation for depression
Latest (Aug 11, 2026): Neuronetics Reports Second Quarter 2026 Financial and Operating Results
Open profile →Twist Bioscience
Synthetic biology · DNA synthesis
Latest (Aug 4, 2026): Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
Open profile →Intellia Therapeutics
Gene & cell engineering · Gene editing inside the body
Latest (Sep 8, 2026): Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Open profile →ClearPoint Neuro
Neurotechnology & BCI · Navigation and delivery systems for procedures inside the brain
Latest (Oct 28, 2026): ClearPoint Neuro Reports Third Quarter 2026 Results
Open profile →Ginkgo Bioworks
Synthetic biology · Cell programming and biosecurity
Latest (Aug 5, 2026): Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland
Open profile →NeuroOne Medical
Neurotechnology & BCI · Thin-film electrodes for brain recording and stimulation
Latest (Oct 5, 2026): NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order
Open profile →NeuroPace
Neurotechnology & BCI · Implanted responsive brain stimulation for epilepsy
Latest (Aug 11, 2026): NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
Open profile →Vivani Medical
Physical augmentation · Implantable drug-delivery devices
Latest (Aug 13, 2026): Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
Open profile →Dexcom
Biomonitoring · Continuous glucose monitoring
Latest (Sep 10, 2026): Dexcom Appoints Glenn Boehnlein to Board of Directors
Open profile →Beam Therapeutics
Gene & cell engineering · Base editing
Latest (Aug 4, 2026): Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Open profile →BioAge Labs
Longevity · Drug development informed by the biology of ageing
Latest (Aug 5, 2026): BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
Open profile →CRISPR Therapeutics
Gene & cell engineering · CRISPR gene-editing medicines
Latest (Oct 19, 2026): CRISPR Therapeutics reports changes involving its directors or officers (Form 8-K, Item 5.02)
Open profile →Lineage Cell Therapeutics
Regeneration · Replacement cell therapies
Latest (Aug 6, 2026): LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Open profile →Prime Medicine
Gene & cell engineering · Prime editing
Latest (Aug 6, 2026): Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
Open profile →Sana Biotechnology
Gene & cell engineering · Regeneration · Engineered cells as medicines
Latest (Aug 10, 2026): Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates
Open profile →Coverage is not an offer to invest. Private ownership does not imply available shares. Sector labels are Sapien Frontier’s own coverage classification, not company claims.
Missing a company? Request future coverage. We add a company when its filings, offering notices or awards can be followed reliably. See what we cover and how often.